PDCD1 and Hodgkins lymphoma: The ORR rate and median OS were higher in azacitidine plus nivolumab plus ipilimumab than azacitidine plus nivolumab group.611 While, high-risk MDS patients after the failure of HMAs did not benefit from pembrolizumab.612 Decitabine in combinatipn with PD-1 inhibitors was also used in classical HL (cHL) treatment.